Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 28.00
XTL's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 28.00 )
Ranked among companies with meaningful PE Ratio only.
XTL' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.37
Current: 28
0
28.37
PE Ratio without NRI 28.00
XTL's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 28.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
XTL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.37
Current: 28
0
28.37
PB Ratio 2.38
XTL's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 2.38 )
Ranked among companies with meaningful PB Ratio only.
XTL' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.46
Current: 2.38
0
2.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.17
XTL's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 1.17 )
Ranked among companies with meaningful Dividend Yield % only.
XTL' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.25
Current: 1.17
0
1.25
5-Year Yield-on-Cost % 1.17
XTL's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 1.17 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XTL' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.25
Current: 1.17
0
1.25

More Statistics

Short Percentage of Float0.00%
52-Week Range $54.71 - 74.21
Shares Outstanding (Mil)1,050,000.00
» More Articles for XTL

Headlines

Articles On GuruFocus.com
Bill Ackman Gives Annual Letter to Shareholders, Apologizes for Losing All That Money Mar 30 2017 
Joel Greenblatt Dividend Stocks in Focus: Garmin Mar 30 2017 
ConocoPhillips Sells Canadian Oil Sands Assets to Cenovus Energy Mar 30 2017 
Samsung Unboxed the Next Big Thing Mar 30 2017 
JPMorgan Upgrades Agnico Eagle Mines Mar 30 2017 
Eldorado Gold Revises Payability Rates at Olympias, Phase II Mar 30 2017 
Don't Fight the Tape; Stock Going Higher Mar 30 2017 
Amazon Enters Middle Eastern Markets Mar 30 2017 
Daimler Is Stronger Now Than Ever Mar 30 2017 
Intel Increases Quarterly Dividend Mar 29 2017 

More From Other Websites
XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors Mar 22 2017
5 Biggest Winners from the Fed Rate Hike Mar 16 2017
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement Mar 01 2017
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in... Feb 13 2017
Telecom ETFs: What Lies Ahead in 2017? Feb 07 2017
ETFs That Sound Alike Are Often Different Jan 26 2017
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program Jan 25 2017
XTL Biopharmaceuticals to Present at Biotech Showcase Dec 19 2016
Dow closes in on 20K mark Dec 13 2016
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements Nov 09 2016
Fed Holds Off Rate Hike for Now: Top 5 Gainers Sep 22 2016
After Friday's Swoon, Should You Run for the Exits? Sep 11 2016
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug... Sep 07 2016
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 Sep 06 2016
Top ETFs In Neglected Telecom Sector Sep 01 2016
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 Aug 11 2016
Dow ETF Treads Water As Key Blue Chips Post Results That Lack Salt Jul 26 2016
Thursday links: a tightrope walk May 26 2016
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016 May 16 2016
New highs for the market? May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK